The latest move in Eli Lilly (LLY) stock comes as the Medicare GLP-1 Bridge program opens wider access to its weight management drugs, alongside strong reported earnings and supportive regulatory and partnership news.

Eli Lilly’s share price has been choppy in the very near term, with a 1-day share price return that declined 1.14% and a 7-day share price return that fell 2.43%. However, the 90-day share price return of 28.89% and 1-year total shareholder return of 56.37% point to strong momentum building around its GLP-1 franchise, recent earnings, and a steady flow of regulatory and partnership updates.

If Eli Lilly’s GLP-1 story has your attention, it may be worth widening your lens to other healthcare-focused opportunities and seeing what stands out in the 40 healthcare AI stocks

Eli Lilly now trades near its recent highs after the GLP-1 Bridge news and reported growth. The key issue is whether that enthusiasm still leaves enough upside to compensate for the risks.

Most Popular Narrative: 18.8% Undervalued

Against the last close of $1,200.06, the most followed narrative on Eli Lilly views fair value at $1,477.03, creating a valuation gap for investors to consider.

You are buying a business already growing at 25% annually, with its most important new drug not yet approved and not yet reflected in any revenue number, at a price that a conservative model says is 27 to 32% below fair value. The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3.

Curious how this narrative gets to that higher fair value for Eli Lilly? It relies on rapid top line expansion, strong profitability, and a future earnings multiple usually associated with mega cap growth leaders. Want to see which specific growth path and margin assumptions sit underneath that price tag, and how far out the model projects those earnings?

Result: Fair Value of $1,477.03 (UNDERVALUED)

However, there are still pressure points for Eli Lilly, including potential GLP-1 pricing cuts and any safety or uptake issues in late-stage obesity and diabetes trials.

Another View on Eli Lilly: What P/E Is Signalling

The first narrative suggests Eli Lilly is meaningfully undervalued, but the current P/E of 42.3x tells a different story. It sits well above the US pharmaceuticals industry average of 15.3x, the peer average of 24.7x, and even the estimated fair ratio of 39.2x.

In plain terms, the stock already carries a rich earnings multiple. If sentiment or growth expectations cool, the market could move closer to that fair ratio and put pressure on the share price. With such a gap between price and peers, are you comfortable with the valuation risk you are taking on?

Next Steps

If the mixed tone around Eli Lilly has you torn, take time while the details are fresh to weigh the company’s risks against its potential rewards in the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Eli Lilly?

Do not stop with Eli Lilly alone. Broaden your watchlist now using focused stock lists that highlight different ways to balance return potential and risk control.

• Hunt for potential standouts that the market may be overlooking by scanning the screener containing 18 high quality undiscovered gems.
• Strengthen the foundation of your portfolio by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results).
• Prioritise resilience and sleep-at-night holdings by assessing opportunities across the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.